贝伐单抗联合替莫唑胺对老年胶质母细胞瘤术后患者预后的影响

目的:探讨贝伐单抗联合替莫唑胺对老年胶质母细胞瘤术后患者预后的影响。方法:选择2014年1月到2016年1月在第四军医大学西京医院诊治的老年胶质母细胞瘤术后患者78例,根据治疗方法的不同分为观察组与对照组各39例,观察组给予替莫唑胺与贝伐单抗联合治疗,对照组只给予替莫唑胺治疗,观察和比较两组患者的的预后情况。结果:观察组与对照组的有效率分别为48.7%和23.1%,观察组显著高于对照组(P0.05)。观察组治疗期间的肝肾反应、胃肠道反应、疲乏、骨髓抑制等毒副反应的发生率明显低于对照组(P0.05)。观察组治疗后的KPS与ECOG评分分别为64.22±2.19分和1.65±0.45分,对照组为56.35±4.50分和2.41±0.51分,组间对比差异明显(P0.05),且与治疗前对比也有明显差异(P0.05)。观察组与对照组的的中位生存时间分别为30个月和21个月,观察组的3年生存率为41.0%,对照组为16.4%,观察组都明显优于对照组(P0.05)。结论:贝伐单抗联合替莫唑胺可显著改善老年胶质母细胞瘤术后患者的生存质量,提高治疗疗效与延长患者的生存时间,且安全性较高。

Effect of Bevacizumab Combined with Temozolomide on the Prognosis of Elderly Postoperative Patients with Glioblastoma

ABSTRACT Objective: To investigate the effect of bevacizumab combined with temozolomide on the prognosis of elderly postop- erative patients with glioblastoma. Methods: 78 elderly postoperative patients with glioblastoma in Xijing hospital from January 2014 to January 2016 were selected and equally divided into the observation group and control group with 39 patients in each group according to different methods of treatment. The observation group was treated by bevacizumab combined with temozolomide, while the control group was given temozolomide treatment, the clinical effect, survival time and quality and life as well as the incidence of adverse reac- tions were observed and compared between two groups of patients. Results: The effective rate of observation group and control group were 48.7% and 23.1% respectively, which was significantly higher in the observation group than that of the control group (P<0.05). Dur- ing the treatment period, the incidence of liver and kidney dysfunction, gastrointestinal reaction, fatigue, bone marrow suppression and other toxic side effects in the treatment group were significantly lowed than those of the control group (P<0.05). The KPS and ECoG scores in the observation group after treatment were 64.22±2.19 points and 1.65±0.45 points, the control group were 56.35±4.50 points and 2.41±0.51 points, significant differences were observed between two groups (P<0.05). The median survival time was 30 months and 21 months in the observation group and control group, and the 3 year survival rate of the observation group was 41%, the control group was 16.4%, the observation group were significantly better than the control group (P<0.05). Conclusion: Bevacizumab combined with temozolomide could improve the quality of life, therapeutic efficacy and prolong the survival time of elderly postoperative patients with glioblastoma.